Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cephalexin
Drug ID BADD_D00412
Description Cephalexin is the first of the first generation cephalosporins.[A179071,A179074] This antibiotic contains a beta lactam and a dihydrothiazide.[A179071] Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.[A179083,Label] Cephalexin was approved by the FDA on 4 January 1971.[L6547]
Indications and Usage For the treatment of respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes; otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Moraxella catarrhalis; skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes; bone infections caused by Staphylococcus aureus and/or Proteus mirabilis; genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae.
Marketing Status Prescription; Discontinued
ATC Code J01DB01
DrugBank ID DB00567
KEGG ID D00263
MeSH ID D002506
PubChem ID 27447
TTD Drug ID D0Z5EM
NDC Product Code 68180-441; 63629-9207; 63629-9200; 63187-205; 54348-555; 69778-930; 61919-606; 68071-5241; 67877-255; 0093-2240; 0143-9897; 65862-018; 68071-3186; 42291-209; 68071-4233; 53002-2182; 80425-0121; 62135-480; 63629-9199; 68071-4516; 53002-2180; 65862-019; 63629-9205; 63629-7740; 50268-151; 67296-0976; 68180-440; 61919-049; 67877-219; 53002-2181; 50090-4423; 69778-931; 70934-840; 60687-163; 50090-0070; 63629-8857; 68071-2249; 68071-5038; 65862-338; 68180-122; 71205-591; 60687-152; 72969-116; 43063-536; 63629-7927; 24979-155; 80425-0005; 50090-3111; 42582-211; 24979-154; 63629-9198; 50090-3057; 42582-212; 68788-7529; 0093-4175; 72287-310; 68071-1585; 50090-4795; 63187-046; 0143-9898; 67877-545; 68071-4355; 50090-5196; 70518-3362; 51655-028; 67296-0037; 63629-7743; 54348-560; 43063-634; 80425-0006; 50268-152; 68071-2246; 68071-5016; 63629-7605; 50090-3291; 66267-982; 68788-7938; 70518-2273; 63629-8856; 0093-3145; 68788-7796; 68180-121; 0093-3147; 50090-3252; 42291-208; 63629-9202; 69043-009; 69043-008; 68788-9539; 42708-070; 42708-017; 50090-3199; 53002-2260; 50090-2749; 63629-9204; 63629-9203; 50090-3202; 63629-8854; 63629-8858; 0093-4177; 63629-8981; 68788-7761; 55289-058; 70518-3066; 43063-678; 70934-040; 68788-9326; 68071-4406; 67877-544; 42708-145; 67877-254; 59651-230; 45865-428; 53002-2540; 70518-3378; 63629-8855; 63629-9206; 0143-9769; 70518-3059; 68071-5011; 43744-061; 63629-9201; 43063-497; 62135-481; 0093-2238; 0143-9770; 50090-0219; 42708-100; 50090-0220; 63629-8980; 68071-4434; 50090-3427; 68788-9713; 68788-9538; 71205-553; 55289-057; 70934-082; 67877-220; 68071-4429; 76420-052
Synonyms Cephalexin | Cefalexin | Cephalexin Hydrochloride | Cephalexin Monohydrochloride, Monohydrate | Cephalexin, (6R-(6alpha,7alpha(R*)))-Isomer | Cephalexin, (6R-(6alpha,7beta(S*)))-Isomer | Cephalexin, (6R-(6alpha,7beta))-Isomer | Cephalexin, Monosodium Salt | Cephalexin Monohydrochloride | Ceporexine | Palitrex | Cephalexin Monohydrate | Cephalexin Dihydride | Cephalexin Hemihydrate | 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- | Cephalexin, Monosodium Salt, (6R-(6alpha,7beta))-Isomer
Chemical Information
Molecular Formula C16H17N3O4S
CAS Registry Number 15686-71-2
SMILES CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=CC=C3)N)SC1)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash erythematous23.03.06.0030.000155%Not Available
Rash generalised23.03.13.0020.000116%Not Available
Rash maculo-papular23.03.13.0040.000310%
Rash papular23.03.13.0170.000077%Not Available
Rash pruritic23.03.12.0020.000155%Not Available
Rash pustular23.03.10.003; 11.01.12.0020.000077%
Renal failure20.01.03.0050.000040%Not Available
Renal tubular acidosis14.01.01.005; 20.05.03.0030.000077%Not Available
Renal tubular necrosis20.01.07.0030.000077%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000030%
Seizure17.12.03.001--
Sepsis11.01.11.003--
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.0030.000116%Not Available
Skin lesion23.03.03.0100.000077%Not Available
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.02.05.034; 19.19.02.002; 17.02.08.0030.000077%Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.0200.000155%
Swelling08.01.03.0150.000155%Not Available
Swelling face23.04.01.018; 10.01.05.0180.000155%Not Available
Swollen tongue23.04.01.014; 10.01.05.015; 07.14.02.0030.000194%Not Available
Tachycardia02.03.02.0070.000116%Not Available
Throat irritation22.02.05.013; 07.05.03.0040.000077%Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombotic thrombocytopenic purpura24.07.06.014; 23.06.01.011; 01.08.01.0050.000077%
Tongue disorder07.14.01.0020.000077%Not Available
Tongue oedema23.04.01.009; 07.14.02.007; 10.01.05.0080.000077%Not Available
Toxic epidermal necrolysis12.03.01.015; 11.07.01.006; 10.01.01.006; 23.03.01.0080.000111%
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages